Poland· PL-100404361
Silodosin Aurovitas
A silodosin product containing silodosinum, registered in Poland by Aurovitas Pharma Polska Sp. z o.o.. The same ATC class is registered in 17 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Silodosin is registered in 17 of 19 countries.
Countries holding a registration under ATC G04CA04 (silodosin), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 10 of them publish a price we can compare per daily dose
Silodosin · ATC G04CA04
17 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Polandprice
- Spainprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of silodosin costs, country by country.
Normalised to the WHO defined daily dose (8 mg), the median price runs from $0.28 in Italy to $1.39 in Switzerland — a ×5.0 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Silodosin · price per daily dose (8 mg)
USD · FX 28 Sept 2026
- CH Switzerland$1.39
- IT Italy$0.28
The record
At a glance
URPL (Poland)- Active substance
- Silodosinum
- Manufacturer
- Aurovitas Pharma Polska Sp. z o.o.
- Country
- Poland (PL)
- ATC code
- G04CA04
- ATC class
- Silodosin
- Defined daily dose
- 8 mg, O
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 7
1 priced- gtin0590999141888530 szt.PLN 13.4
- gtin05909991418854
- gtin05909991418861
- gtin05909991418878
- gtin05909991418892
- gtin05909991418908
- gtin05909991418915
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
148 interactions on record for silodosin.
Graded by severity as the source publishes them — 9 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Silodosin · interactions on record
148 records
- 9 severe
- 139 moderate
Most severe, free to view
- KetoconazoleH02CA03severe
- ClarithromycinJ01FA09severe
- KetoconazoleJ02AB02severe
- Darunavir and cobicistatJ05AR14severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Silodosin in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SpainSIDARSO 4 MG CAPSULAS DURAS EFGKrka D.D. Novo Mesto
- CzechiaSILODOSIN RECORDATIRECORDATI Ireland Limited, Ringaskiddy Co. Cork
- United StatesSilodosinAmneal Pharmaceuticals NY LLC
- ItalySILODOSINA ARISTOARISTO PHARMA GMBH
- FranceSILODOSINE ARROW 4 mg, géluleARROW GENERIQUES
- SwitzerlandSilodosin Spirig HC 4 mg, HartkapselnSpirig HealthCare AG
- NetherlandsSilodosin Recordati 4 mg, capsules hardRecordati Ireland Ltd. (Co. Cork)
- BelgiumSilodosin AB 4 mgAurobindo
Authorised across Europe · EMA
The same active substance is authorised in 17 EEA countries. Names it is sold under:
- Belgium · Silodosin Ab
- Bulgaria · Пирсео, Сидарсо
- Germany · Silbesan, Silodosin Al
- Spain · Silodosina Abamed, Silodosina Alter
- France · Silodosine Arrow, Silodosine Biogaran
- Croatia · Niksol, Sidarso
- Hungary · Pirseo, Sidarso
- Iceland · Silodosin Recordati, Silodyx
- Italy · Silodosina Aristo, Silodosina Aurobindo
- Liechtenstein · Silodosin Recordati, Silodyx
- Lithuania · Sidarso
- Netherlands · Silodosin Aurobindo, Silodosine Amarox
- Norway · Silodosin Recordati, Silodyx
- Portugal · Silodosin Ipca, Silodosin Msn
- Romania · Sidarso
- Slovenia · Sidarso
- Slovakia · Sidarso, Silodosin
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/4fc5a02e-df59-4f8e-85ff-77f5bafe2716 GET /v1/drugs/4fc5a02e-df59-4f8e-85ff-77f5bafe2716?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Kapsułki twarde",
"source": "urpl",
"strength": "4 mg",
"packaging": "05909991418854 ¦ Rp ¦ 134714\n5 kaps.\n05909991418861 ¦ Rp ¦ 134715\n10 kaps.\n05909991418878 ¦ Rp ¦ 134716\n20 kaps.\n05909991418885 ¦ Rp ¦ 134717\n30 kaps.\n05909991418892 ¦ Rp ¦ 134718\n50 kaps.\n05909991418908 ¦ Rp ¦ 134719\n90 kaps.\n05909991418915 ¦ Rp ¦ 134720\n100 kaps.",
"substance": "Silodosinum 4 mg",
"common_name": "Silodosinum",
"pl_product_id": "100404361",
"pozwolenie_nr": "25635",
"auth_procedure": "DCP",
"authorisation_validity": "Bezterminowe"
}See everything about silodosin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.